Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Core Insights - Hoth Therapeutics announced positive interim results from the Phase 2a clinical trial, CLEER-001, for HT-001, which showed a 50% reduction in pruritus severity in patients experiencing skin toxicities from EGFR inhibitors [1][3][8] Group 1: Clinical Trial Results - The mean pruritus score decreased from 1.6 on Day 1 to 0.8 by Day 21, indicating significant symptom relief [1][8] - Rapid improvement was noted, with mean scores reaching 1.0 by Day 7, and some patients achieving complete resolution of pruritus within the 21-day period [8][9] - HT-001 was well tolerated, with no serious adverse events reported related to the treatment [8][9] Group 2: Product and Company Overview - HT-001 is a proprietary, non-steroidal topical formulation aimed at treating pruritus and inflammatory skin conditions associated with targeted cancer therapies [5] - The company focuses on developing innovative therapies for patients with high unmet medical needs, emphasizing a patient-centric approach in its research and development efforts [6]